الفهرس | Only 14 pages are availabe for public view |
Abstract As systemic treatment such as chemotherapy and hormonal therapy have become ever more effective, the median survival of women with metastatic disease has continued to improve, as has the management of symptoms resulting from distant disease sites. Thus, new clinical questions have emerged regarding surgery of the primary site in those women with metastatic disease and a respectable intact primary tumor. Patients with metastatic or stage IV breast cancer have limited therapeutic options, and the mainstay of treatment remains systemic chemotherapy. Traditionally, the role of surgery has been confined to strict palliation. The aim of this study was to assess impact of primary tumor resection on response and survival and quality of life in metastatic breast cancer patients This study was a prospective study assessing the effect of primary tumor resection on response and survival in metastatic breast cancer patients attending to oncology department menoufia university hospitals There was statistically significant difference as regard overall survival between the 2 groups (P value <0.001). The mean survival for surgery group was 39.10 and 28.04 for no surgery group (figure 5). with mean time to progression 26.16 (22.1 – 30.2) in surgery group and 13.81 (11.5 – 16.1)in no surgery group . In our study we found that Two years survival rate was 73.8% in surgery group compared to 38.9% in no surgery group. There wasstatistically significant difference in time to progression between surgery group and no surgery group (p value <0.001). We concluded that Primary tumor resection did increase survival in metastatic breast cancer patients and increased time to progression. So, the current strategy of treatment especially the surgical role in metastatic patients should be revised. |